Drug Trial Radar · NCT03895203
A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
852
Actual
Start
Apr 3, 2019
Primary completion
Aug 17, 2021
Study completion Jul 11, 2022
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Mar 29, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of subjects with active Psoriatic Arthritis (PsA).
Conditions
- Psoriatic Arthritis
Interventions
BimekizumabDrug
Subjects will receive bimekizumab at pre-specified time-points.
AdalimumabDrug
Adalimumab will be administered according to the labeling recommendations.
PlaceboOther
Subjects will receive placebo at pre-specified time-points.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With an American College of Rheumatology (ACR) 50 Response at Week 16Time frame: Week 16
Locations
136 sites in 14 countries. Site status is shown where the registry gives one.
Pa0010 50017
Phoenix, Arizona
Pa0010 50035
San Diego, California
Pa0010 50004
Tustin, California
Pa0010 50033
Palm Harbor, Florida
Pa0010 50037
Tampa, Florida
Pa0010 50039
Atlanta, Georgia
Pa0010 50028
Lexington, Kentucky
Pa0010 50015
Hagerstown, Maryland
Pa0010 50016
St Louis, Missouri
Pa0010 50029
Albuquerque, New Mexico
Pa0010 50010
Brooklyn, New York
Pa0010 50125
Charlotte, North Carolina
Pa0010 50040
Dayton, Ohio
Pa0010 50020
Duncansville, Pennsylvania
Pa0010 50006
Wyomissing, Pennsylvania
Pa0010 50008
Johnston, Rhode Island
Pa0010 50007
Orangeburg, South Carolina
Pa0010 50001
Jackson, Tennessee
Pa0010 50012
Memphis, Tennessee
Pa0010 50002
Austin, Texas
Pa0010 50049
Corpus Christi, Texas
Pa0010 50051
Houston, Texas
Pa0010 50036
Mesquite, Texas
Pa0010 50009
Waco, Texas
Pa0010 50050
Beckley, West Virginia
Pa0010 30005
Camberwell, Australia
Pa0010 30002
Clayton, Australia
Pa0010 30008
Hobart, Australia
Pa0010 30003
Maroochydore, Australia
Pa0010 30007
Victoria Park, Australia
Pa0010 30006
Woodville, Australia
Pa0010 40003
Genk, Belgium
Pa0010 40002
Leuven, Belgium
Pa0010 40059
Mons, Belgium
Pa0010 50041
Québec, Canada
Pa0010 50042
Rimouski, Canada
Pa0010 50043
Sidney, Canada
Pa0010 50044
Trois-Rivières, Canada
Pa0010 40061
Brno, Czechia
Pa0010 40065
Brno, Czechia
Showing 40 of 136 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.